As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting publications on pediatric CML and from LMICs.

Read Professor Hughes' CML publications of the month: September - October 2025

Clinical CML papers

• Estimating the burden of chronic stress through allostatic load in patients with chronic myeloid leukemia
  Miranda-Galvis M et al. Leukemia, September 2025 (epub ahead of print)
• Changes in common blood parameters after discontinuation of tyrosine kinase inhibitors for chronic myeloid leukemia
  Fernando F et al. EJHaem, October 2025 – open access publication
• Impact of ASXL1 at diagnosis in patients with chronic myeloid leukemia receiving frontline potent tyrosine kinase inhibitors: high risk of kinase domain mutations
  Shanmunagathan N et al. Blood, September 2025 (epub ahead of print)
• SOHO State of the Art updates and next questions |Choosing the best frontline BCR::ABL1 tyrosine kinase inhibitor in CML – How to define the treatment value? 
  Haddad FG et al. Clin Lymphoma Myeloma Leuk, October 2025 (epub ahead of print)
• Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase
  Atallah E et al. Hematology, October 2025 (epub ahead of print) – open access publication
• Treatment-free remission in chronic phase chronic myeloid leukemia after nilotinib de-escalation: 96-week update of the DANTE Study
  Iurlo A et al. Hematol Oncol, September 2025 – open access publication
• Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia
  Atallah EL et al. Leuk Res, October 2025 – open access publication
• A newcomer in allosteric therapy for Ph+ leukemias
  Delphine Rea. Blood, October 2025 – open access publication
• Therapeutic positioning of asciminib in chronic myeloid leukemia patients previously treated with multiple tyrosine kinase inhibitors in Quatar - Review
  Ghasoub R et al. Discov Oncol, October 2025 – open access publication
• Predicting treatment-free remission in chronic myeloid leukemia patients using an integrated model of tumor-immune dynamics
  Fassoni AC et al. NPJ Syst Biol Appl, October 2025 – open access publication
• BCR::ABL1 tyrosine kinase inhibitors during pregnancy, a disproportionality analysis of ligibase
  Cabannes-Hamy A et al. Clin Pharmacol Ther, September 2025 – open access publication
• Molecular milestones and survival outcomes of ponatinib treatment in patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: A real-world analysis
  Tseng TC et al. Clin Lymphoma Myeloma Leuk, September 2025 (epub ahead of print)
• Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML
  Purhonen M et al. Leukemia, September 2025 (epub ahead of print) – open access publication
• Olverembatinib in accelerated-phase chronic myeloid leukemia: Efficacy and safety evaluation
  Yuan M et al. Haematologica, October 2025 (epub ahead of print) – open access publication
• Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia
  McCormick B et al. Leuk Lymphoma, October 2025 (epub ahead of print)
• Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study
  Sicuranza A et al. Cancer, October 2025 – open access publication
  
• Primary asciminib resistance in a chronic myeloid leukemia patient with the atypical BCR::ABL1 e13a3 transcript: a case study
  Jung BK et al. Haematologica, October 2025 (epub ahead of print) – open access publication
• Clinical and biological predictors of treatment-free remission in CML – Review
  Sutton E et al. Leuk Lymphoma, October 2025 (epub ahead of print)
• Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: the RODEO Study
  Lokhorst DN et al. Haematologica, October 2025 (epub ahead of print) – open access publication

Scientific CML papers

• Advancing our understanding of the influence of myeloid derived suppressor cells in chronic myeloid leukemia - Review
  Meng X et al. J Cancer Res Clin Oncol, September 2025 – open access publication
• Uncommon phenotypes of BCR::ABL1-positive chronic myelogenous leukemia
  Jajosky AN et al. Haematologica, September 2025 – open access publication
• An automated cartridge-based microfluidic system for real-time quantification of BCR::ABL1 transcripts in CML: An Italian Experience
  Danzero AC et al. Int J Mol Sci, September 2025 – open access publication

Pediatric CML papers

• An old leukaemia in young patients – Genetic characteristics of paediatric chronic myeloid leukemia – Review
  Metzler M et al. Br J Haematol, Sept 2025 (epub ahead of print)
• Children with chronic phase chronic myeloid leukemia: Characteristics and outcomes from the International Registry of Childhood CML
  Millot F et al. Haematologica, October 2025 (epub ahead of print) – open access publication
• Pediatric chronic myeloid leukemia: A decade of clinical experience at the NBL specialized hospital for children
  Bourusky M et al. Leuk Res Rep, October 2025 – open access publication
• Safety profiles of dasatinib in pediatric patients: A real-world pharmacovigilance assessment based on the FAERS database
  Yang Y et al. Jp J Clin Oncol, October 2025 (epub ahead of print) – open access publication

LMIC papers

• Clinical presentation of chronic myeloid leukaemia and its correlation with haematological parameters in Kenya
  Othieno-Abinya, N. A. et al. Journal of Cancer Biomoleculars and Therapeutics, July 2025 
  – open access publication
• Revisiting treatment-free remission: A case of late molecular recurrence in chronic myeloid leukemia
  Sharma V et al. J Assoc Physicians India, September 2025 – open access publication
• Impact of dasatinib on female reproductive health in Philadelphia-positive leukemia patients
  Kintada S et al. Indian J Hematol Blood Transfus, October 2025
• Imatinib induced thyroid dysfunction in BCR::ABL1 positive chronic myeloid leukemia patients: Sokal Score as a predictor
  Ahmed IO et al. Indian J Hematol Blood Transfus, October 2025